U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793371) titled 'AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF' on Jan. 21.
Brief Summary: This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
Study Start Date: Jan., 2025
Study Type: INTERVENTIONAL
Condition:
Symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF)
Intervention:
DRUG: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
CK-4021586 administered orally
DRUG: Placebo to match CK-4021586
Placebo administered orally
Recruitment Status: RECRUITING
Sponsor: Cytokinetics
Published by HT Digital Content Services with per...